A Phase 3 interventional study of Paliperidone extended-release (JNS007ER) in Schizophrenia, sponsored by Janssen Pharmaceutical K.K.. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-09-28.
Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.
Among the 115 studies testing paliperidone in Schizophrenia, this one is the 47th largest by enrollment, is one of 5 that started in 2006, is one of 41 in phase 3, and was the 74th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Alejandro Alva · Sites in United States
Ages 18–65
Jiangsu Province Nanjing Brain Hospital · Sites in China
Ages 18–65
Sher-E-Bangla Medical College · Sites in Bangladesh
Ages 18–60
By country, each count listing its studies:
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 7 · Phase 3 42 · Phase 4 42
First in 2003; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 228 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 115 interventional studies. Of the 104 that completed or were terminated, 42 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Pharmaceutical K.K., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 68th largest by enrollment of the 176 interventional ones that give a count, is one of 16 that started in 2006, is one of 74 in phase 3, and was the 161st registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing paliperidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies testing paliperidone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety of JNS007ER 3-12 mg once daily in patients with schizophrenia over a long term period.
This is a 48-week, multicenter, open-label (all people know the identity of the intervention), non-controlled, arbitrary-dose study. The patients included in this study are those who participated in the preceding double-blind (neither physician nor patient knows the treatment that the patient receives) comparative trial (study JNS007ER-JPN-S31) of JNS007ER and completed the study, or those who remained in the study up to the evaluation at 2 weeks and discontinued the study after that for insufficient treatment efficacy. The study will assess the safety of JNS007ER in the clinical recommended dose range in a long term treatment. The dosage will be started at 6 mg/day, and it can be increased or decreased 3 mg at a time depending on the patient's symptom within the range of 3 mg/day to 12 mg/day. For dose adjustments, the investigator will evaluate the psychiatric symptoms before defining the dose change.
Detailed Description: Extended description of the protocol, including more technical information (as compared to the Brief Summary) if desired. Do not include the entire protocol; do not duplicate information recorded in other data elements, such as eligibility criteria or outcome measures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Paliperidone extended-release (JNS007ER)
Type= range, unit= mg, number= 3-12, form= tablet, route= oral use. JNS007ER within the range of 3, 6, 9 and 12 mg will be orally administered once daily for 48 weeks.
Incidence of Adverse Events
The incidence of adverse events was measured by the percentage of patients who presented one or more adverse events.
Time frame: 48 weeks
Change From Baseline in Positive and Negative Syndrome Scale (PANSS)
PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).
Time frame: Baseline, Week 48
Change From Baseline in Clinical Global Impression - Severity (CGI-S)
The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill patients".
Time frame: Baseline, Week 48
This study comprises patients who have participated in previous study JNS007ER-JPN-S31 (NCT00396565) and new patients. New patients were classified as group NO/PAL. Patients entering from study JNS007ER-JPN-S31 were classified according to their origin groups: placebo group (PLA/PAL), paliperidone group (PAL/PAL), and olanzapine group (OLZ/PAL).
| Milestone | NO/PAL Group | PLA/PAL Group | PAL/PAL Group | OLZ/PAL |
|---|---|---|---|---|
| Started | 7 | 92 | 97 | 32 |
| Completed | 5 | 51 | 53 | 12 |
| Not completed | 2 | 41 | 44 | 20 |
| Withdrew: Withdrawal by subject | 0 | 8 | 12 | 5 |
| Withdrew: Lack of efficacy | 0 | 8 | 10 | 5 |
| Withdrew: Worsening of complications | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 1 | 19 | 14 | 9 |
| Withdrew: Physician decision | 1 | 5 | 7 | 1 |
PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).
| scores on a scale | NO/PAL | PLA/PAL Group | PAL/PAL Group | OLZ/PAL |
|---|---|---|---|---|
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) | -13.4 ± 31.93 | -11.1 ± 20.84 | -17.2 ± 22.15 | 2.8 ± 20.67 |
The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill patients".
| scores on a scale | NO/PAL | PLA/PAL Group | PAL/PAL Group | OLZ/PAL |
|---|---|---|---|---|
| Change From Baseline in Clinical Global Impression - Severity (CGI-S) | -0.6 ± 1.27 | -0.6 ± 1.20 | -0.7 ± 1.24 | 0.1 ± 1.01 |
The incidence of adverse events was measured by the percentage of patients who presented one or more adverse events.
| percentage of patients | Entire Group |
|---|---|
| Incidence of Adverse Events | 97.4 |
Collected over 48 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Entire Group | — | 10/228 (4.4%) | 222/228 (97.4%) |
| Event | Entire Group |
|---|---|
| SchizophreniaPsychiatric disorders | 3/228 |
| PneumoniaInfections and infestations | 2/228 |
| InsomniaPsychiatric disorders | 1/228 |
| AkathisiaNervous system disorders | 1/228 |
| Pulmonary aspirationRespiratory, thoracic and mediastinal disorders | 1/228 |
| Multiple organ failureGeneral disorders | 1/228 |
| ECG corrected QT interval prolongedCardiac disorders | 1/228 |
| OverdoseGeneral disorders | 1/228 |
| Event | Entire Group |
|---|---|
| Blood prolactin increasedInvestigations | 91/228 |
| NasopharyngitisInfections and infestations | 77/228 |
| SchizophreniaPsychiatric disorders | 69/228 |
| Weight increasedGeneral disorders | 50/228 |
| Extrapyramidal disorderNervous system disorders | 39/228 |
| ConstipationGastrointestinal disorders | 32/228 |
| Blood creatine phosphokinase increasedMetabolism and nutrition disorders | 28/228 |
| Blood triglycerides increasedMetabolism and nutrition disorders | 23/228 |
| InsomniaPsychiatric disorders | 23/228 |
| EczemaSkin and subcutaneous tissue disorders | 20/228 |
| Age Continuous(years) | NO/PAL Group | PLA/PAL Group | PAL/PAL Group | OLZ/PAL | Total |
|---|---|---|---|---|---|
| Mean | 35.6 ± 14.8 | 46.6 ± 15.5 | 42.0 ± 14.1 | 46.3 ± 14.0 | 44.3 ± 14.9 |
| Sex: Female, Male(Participants) | NO/PAL Group | PLA/PAL Group | PAL/PAL Group | OLZ/PAL | Total |
|---|---|---|---|---|---|
| Female | 3 | 44 | 46 | 20 | 113 |
| Male | 4 | 48 | 51 | 12 | 115 |
No study locations are listed for this record.
The record gives a start of Jun 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paliperidone